Crinetics Pharmaceuticals, Inc. financial data

Symbol
CRNX on Nasdaq
Location
San Diego, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1928% % 21%
Debt-to-equity 10% % -28%
Return On Equity -35% % 2.8%
Return On Assets -32% % -0.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 94,891,840 shares 2.3%
Common Stock, Shares, Outstanding 94,548,000 shares 17%
Entity Public Float $3,500,000,000 USD 250%
Common Stock, Value, Issued $881,000 USD
Weighted Average Number of Shares Outstanding, Basic 94,215,000 shares 18%
Weighted Average Number of Shares Outstanding, Diluted 94,215,000 shares 18%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $1,031,000 USD 158%
Revenue from Contract with Customer, Excluding Assessed Tax $143,000 USD
Research and Development Expense $313,571,000 USD 43%
General and Administrative Expense $165,812,000 USD 87%
Operating Income (Loss) $477,848,000 USD -56%
Nonoperating Income (Expense) $54,751,000 USD 63%
Net Income (Loss) Attributable to Parent $423,097,000 USD -52%
Earnings Per Share, Basic -4 USD/shares -21%
Earnings Per Share, Diluted -4 USD/shares -21%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $110,901,000 USD -65%
Cash, Cash Equivalents, and Short-term Investments $1,100,000,000 USD 28%
Other Assets, Current $4,808,000 USD 224%
Assets, Current $1,121,275,000 USD 28%
Property, Plant and Equipment, Net $14,377,000 USD 23%
Operating Lease, Right-of-Use Asset $41,147,000 USD -7%
Other Assets, Noncurrent $14,150,000 USD 608%
Assets $1,196,031,000 USD 28%
Accounts Payable, Current $6,109,000 USD 24%
Liabilities, Current $74,155,000 USD 38%
Operating Lease, Liability, Noncurrent $42,703,000 USD -5.4%
Other Liabilities, Noncurrent $2,894,000 USD 466%
Liabilities $123,862,000 USD 19%
Common Stocks, Including Additional Paid in Capital $2,364,699,000 USD 39%
Accumulated Other Comprehensive Income (Loss), Net of Tax $2,194,000 USD 7.7%
Retained Earnings (Accumulated Deficit) $1,294,612,000 USD -49%
Stockholders' Equity Attributable to Parent $1,072,169,000 USD 29%
Liabilities and Equity $1,196,031,000 USD 28%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $88,452,000 USD -67%
Net Cash Provided by (Used in) Financing Activities $4,437,000 USD -99%
Net Cash Provided by (Used in) Investing Activities $85,961,000 USD -27919%
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 94,548,000 shares 17%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $169,976,000 USD -150%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $112,201,000 USD -65%
Deferred Tax Assets, Valuation Allowance $281,784,000 USD 52%
Deferred Tax Assets, Gross $291,535,000 USD 50%
Operating Lease, Liability $49,144,000 USD -6.5%
Payments to Acquire Property, Plant, and Equipment $1,239,000 USD -7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $422,941,000 USD -54%
Lessee, Operating Lease, Liability, to be Paid $73,640,000 USD -9.5%
Property, Plant and Equipment, Gross $21,420,000 USD 15%
Operating Lease, Liability, Current $6,441,000 USD -13%
Lessee, Operating Lease, Liability, to be Paid, Year Two $6,999,000 USD -6.3%
Lessee, Operating Lease, Liability, to be Paid, Year One $6,795,000 USD 250%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $24,496,000 USD -15%
Lessee, Operating Lease, Liability, to be Paid, Year Three $7,209,000 USD 6.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $10,689,000 USD 54%
Lessee, Operating Lease, Liability, to be Paid, Year Four $7,425,000 USD 6.1%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Share-based Payment Arrangement, Expense $88,149,000 USD 42%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%